https://max-website20-images.s3.ap-south-1.amazonaws.com/MHC_Digital_Treatments_Available_For_Blood_Cancer_Part_13_925x389pix_150322n_01_dc4d07f20e.jpg" alt="Is Blood Cancer Curable - Types, Diagnosis & Cure | Max Hospital">

The "Cancer and Deaths Dataset: 1990~2019 Globally" is a comprehensive dataset containing information on cancer incidence and mortality rates across the world from 1990 to 2019.

The dataset is an excellent resource for researchers, healthcare professionals, and policymakers who are interested in understanding the global burden of cancer and its impact on populations.

[ Total 9 file , 160 columns, All the countries, 30Years data ]

>In 2017, 9.6 million people are estimated to have died from the various forms of cancer. Every sixth death in the world is due to cancer, making it the second leading cause of death – second only to cardiovascular diseases.1

Progress against many other causes of deaths and demographic drivers of increasing population size, life expectancy and — particularly in higher-income countries — aging populations mean that the total number of cancer deaths continues to increase. This is a very personal topic to many: nearly everyone knows or has lost someone dear to them from this collection of diseases.

## Data vastness of this dataset: 01. annual-number-of-deaths-by-cause data. 02. total-cancer-deaths-by-type data. 03. cancer-death-rates-by-age data. 04. share-of-population-with-cancer-types data. 05. share-of-population-with-cancer data. 06. number-of-people-with-cancer-by-age data. 07. share-of-population-with-cancer-by-age data. 08. disease-burden-rates-by-cancer-types data. 09. cancer-deaths-rate-and-age-standardized-rate-index data.

Cancer death rates by county, all races (includes Hispanic/Latino), all sexes, all ages, 2019-2023. Death data were provided by the National Vital Statistics System. Death rates (deaths per 100,000 population per year) are age-adjusted to the 2000 US standard population (20 age groups: <1, 1-4, 5-9, ... , 80-84, 85-89, 90+). Rates calculated using SEER*Stat. Population counts for denominators are based on Census populations as modified by the National Cancer Institute. The US Population Data File is used for mortality data. The Average Annual Percent Change is based onthe APCs calculated by the Joinpoint Regression Program (Version 4.9.0.0). Due to data availability issues, the time period used in the calculation of the joinpoint regression model may differ for selected counties. Counties with a (3) after their name may have their joinpoint regresssion model calculated using a different time period due to data availability issues.

Age-standardised rate of mortality from oral cancer (ICD-10 codes C00-C14) in persons of all ages and sexes per 100,000 population.RationaleOver the last decade in the UK (between 2003-2005 and 2012-2014), oral cancer mortality rates have increased by 20% for males and 19% for females1Five year survival rates are 56%. Most oral cancers are triggered by tobacco and alcohol, which together account for 75% of cases2. Cigarette smoking is associated with an increased risk of the more common forms of oral cancer. The risk among cigarette smokers is estimated to be 10 times that for non-smokers. More intense use of tobacco increases the risk, while ceasing to smoke for 10 years or more reduces it to almost the same as that of non-smokers3. Oral cancer mortality rates can be used in conjunction with registration data to inform service planning as well as comparing survival rates across areas of England to assess the impact of public health prevention policies such as smoking cessation.References:(1) Cancer Research Campaign. Cancer Statistics: Oral – UK. London: CRC, 2000.(2) Blot WJ, McLaughlin JK, Winn DM et al. Smoking and drinking in relation to oral and pharyngeal cancer. Cancer Res 1988; 48: 3282-7. (3) La Vecchia C, Tavani A, Franceschi S et al. Epidemiology and prevention of oral cancer. Oral Oncology 1997; 33: 302-12.Definition of numeratorAll cancer mortality for lip, oral cavity and pharynx (ICD-10 C00-C14) in the respective calendar years aggregated into quinary age bands (0-4, 5-9,…, 85-89, 90+). This does not include secondary cancers or recurrences. Data are reported according to the calendar year in which the cancer was diagnosed.Counts of deaths for years up to and including 2019 have been adjusted where needed to take account of the MUSE ICD-10 coding change introduced in 2020. Detailed guidance on the MUSE implementation is available at: https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/articles/causeofdeathcodinginmortalitystatisticssoftwarechanges/january2020Counts of deaths for years up to and including 2013 have been double adjusted by applying comparability ratios from both the IRIS coding change and the MUSE coding change where needed to take account of both the MUSE ICD-10 coding change and the IRIS ICD-10 coding change introduced in 2014. The detailed guidance on the IRIS implementation is available at: https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/bulletins/impactoftheimplementationofirissoftwareforicd10causeofdeathcodingonmortalitystatisticsenglandandwales/2014-08-08Counts of deaths for years up to and including 2010 have been triple adjusted by applying comparability ratios from the 2011 coding change, the IRIS coding change and the MUSE coding change where needed to take account of the MUSE ICD-10 coding change, the IRIS ICD-10 coding change and the ICD-10 coding change introduced in 2011. The detailed guidance on the 2011 implementation is available at https://webarchive.nationalarchives.gov.uk/ukgwa/20160108084125/http://www.ons.gov.uk/ons/guide-method/classifications/international-standard-classifications/icd-10-for-mortality/comparability-ratios/index.htmlDefinition of denominatorPopulation-years (aggregated populations for the three years) for people of all ages, aggregated into quinary age bands (0-4, 5-9, …, 85-89, 90+)

BackgroundThe exponential growth of the cancer burden attributable to metabolic factors deserves global attention. We investigated the trends of cancer mortality attributable to metabolic factors in 204 countries and regions between 1990 and 2019.MethodsWe extracted data from the Global Burden of Disease Study (GBD) 2019 and assessed the mortality, age-standardized death rate (ASDR), and population attributable fractions (PAFs) of cancers attributable to metabolic factors. Average annual percentage changes (AAPCs) were calculated to assess the changes in the ASDR. The cancer mortality burden was evaluated according to geographic location, SDI quintiles, age, sex, and changes over time.ResultsCancer attributable to metabolic factors contributed 865,440 (95% UI, 447,970-140,590) deaths in 2019, a 167.45% increase over 1990. In the past 30 years, the increase in the number of deaths and ASDR in lower SDI regions have been significantly higher than in higher SDI regions (from high to low SDIs: the changes in death numbers were 108.72%, 135.7%, 288.26%, 375.34%, and 288.26%, and the AAPCs were 0.42%, 0.58%, 1.51%, 2.36%, and 1.96%). Equatorial Guinea (AAPC= 5.71%), Cabo Verde (AAPC=4.54%), and Lesotho (AAPC=4.42%) had the largest increase in ASDR. Large differences were observed in the ASDRs by sex across different SDIs, and the male-to-female ratios of ASDR were 1.42, 1.50, 1.32, 0.93, and 0.86 in 2019. The core population of death in higher SDI regions is the age group of 70 years and above, and the lower SDI regions are concentrated in the age group of 50-69 years. The proportion of premature deaths in lower SDI regions is significantly higher than that in higher SDI regions (from high to low SDIs: 2%, 4%, 7%, 7%, and 9%). Gastrointestinal cancers were the core burden, accounting for 50.11% of cancer deaths attributable to metabolic factors, among which the top three cancers were tracheal, bronchus, and lung cancer, followed by colon and rectum cancer and breast cancer.ConclusionsThe cancer mortality burden attributable to metabolic factors is shifting from higher SDI regions to lower SDI regions. Sex differences show regional heterogeneity, with men having a significantly higher burden than women in higher SDI regions but the opposite is observed in lower SDI regions. Lower SDI regions have a heavier premature death burden. Gastrointestinal cancers are the core of the burden of cancer attributable to metabolic factors.

Number and rate of new cancer cases diagnosed annually from 1992 to the most recent diagnosis year available. Included are all invasive cancers and in situ bladder cancer with cases defined using the Surveillance, Epidemiology and End Results (SEER) Groups for Primary Site based on the World Health Organization International Classification of Diseases for Oncology, Third Edition (ICD-O-3). Random rounding of case counts to the nearest multiple of 5 is used to prevent inappropriate disclosure of health-related information.

Rank, number of deaths, percentage of deaths, and age-specific mortality rates for the leading causes of death, by age group and sex, 2000 to most recent year.

BackgroundUnderstanding the effects of demographic drivers on lung cancer mortality trends is critical for lung cancer control. We have examined the drivers of lung cancer mortality at the global, regional, and national levels.MethodsData on lung cancer death and mortality were extracted from the Global Burden of Disease (GBD) 2019. Estimated annual percentage change (EAPC) in the age-standardized mortality rate (ASMR) for lung cancer and all-cause mortality were calculated to measure temporal trends in lung cancer from 1990 to 2019. Decomposition analysis was used to analyze the contributions of epidemiological and demographic drivers to lung cancer mortality.ResultsDespite a non-significant decrease in ASMR [EAPC = −0.31, 95% confidence interval (CI): −1.1 to 0.49], the number of deaths from lung cancer increased by 91.8% [95% uncertainty interval (UI): 74.5–109.0%] between 1990 and 2019. This increase was due to the changes in the number of deaths attributable to population aging (59.6%), population growth (56.7%), and non-GBD risks (3.49%) compared with 1990 data. Conversely, the number of lung cancer deaths due to GBD risks decreased by 19.8%, mainly due to tobacco (−12.66%), occupational risks (−3.52%), and air pollution (−3.47%). More lung cancer deaths (1.83%) were observed in most regions, which were due to high fasting plasma glucose levels. The temporal trend of lung cancer ASMR and the patterns of demographic drivers varied by region and gender. Significant associations were observed between the contributions of population growth, GBD risks and non-GBD risks (negative), population aging (positive), and ASMR in 1990, the sociodemographic index (SDI), and the human development index (HDI) in 2019.ConclusionPopulation aging and population growth increased global lung cancer deaths from 1990 to 2019, despite a decrease in age-specific lung cancer death rates due to GBD risks in most regions. A tailored strategy is needed to reduce the increasing burden of lung cancer due to outpacing demographic drivers of epidemiological change globally and in most regions, taking into account region- or gender-specific risk patterns.

Introduction. The analysis looks at mental and physical health data from 2000-2019 from various sources the main one being the World Health Organization (WHO).

Task: Analyze health data to gain insights into current consumers health patterns globally and in Kenya to be utilized to make data driven decisions.

Stakeholders: -Company founders and C-suite teams. -Human Resource and Mental Health Professionals. -Government policy makers.

Analysis Objectives: -What is the trend in global and local consumer mental and physical health? -How can these trends influence public and corporate strategies?

ROCCC of Data: A good data source is ROCCC which stands for Reliable, Original, Comprehensive, Current, and Cited.

-Reliablity — High — The data comes from global population sample data sources.

-Originality — LOW — Third party provider (WHO).

-Comprehensive — HIGH — There are several variables summarized into between 1,700-10,980 observations for a period of over 15 years which was fairly comprehensive.

-Current — MID — Data is 3 years old and may not be as relevant as there is no covid data updated to it.

-Cited — HIGH — Data collected from a reliable third party that comprehensively reports its data collection process publicly.

Overall, the dataset is good quality data however its recommended that an updated analysis be done on the health trends during and post-covid.

Key Insights

-There is a higher average suicide rate in men than women both globally and also in Kenya.

-Kenya has a higher average suicide rate for both genders compared to the global average as at 2019.

-The average probability of death between the age of 30 to 70 from from any of cardiovascular disease, cancer, diabetes or chronic respiratory disease in Kenya has been decreasing since 2008 however an increase has been observed since 2016.

-There has been a significant increase in the prevalence of alcohol and substance use disorder in Kenya, moreover, the prevalence in the country increases as the prevalence of anxiety disorders, eating disorders and schizophrenia increases according to the Kenyan correlation heat map.

-As evident on the correlation heat map the prevalence various mental health issues have an impact on each other.

-The global probability of dying between age 30 and 70 from any of cardiovascular disease, cancer, diabetes or chronic respiratory disease has been falling significantly since the 2000s, however, its only been steadily decreasing in Kenya. Men are also at a higher risk of death from these diseases compared to women both globally and locally in Kenya.

-The probability of dying between age 30 and 70 from any of cardiovascular disease, cancer, diabetes or chronic respiratory disease in Kenya has been observed to be significantly inversely proportional to the prevalence of alcohol, substance use anxiety and eating disorders.

-Suicide rates have been observed to not have a significant direct relationship with any mental health disorders both globally and locally however the most significant correlation is the probability of dying between age 30 and 70 from any of cardiovascular disease, cancer, diabetes or chronic respiratory disease in the global analysis.

-Globally a significant inverse relationship between road traffic death rate and eating disorders has been observed however there is a slightly significant relationship between depressive disorders and road traffic death which should be an indicator for further research.

-In Kenya, its been observed that road traffic deaths are inversely proportional to the probability of dying between age 30 and 70 from any of cardiovascular disease, cancer, diabetes or chronic respiratory disease but directly proportional to eating, anxiety, alcohol and substance use disorders.

-Depressive disorders is the most significant variable that has an impact on suicide rates in Kenya therefore further study can look into the impact of depression on attempted and reported suicide cases and other factors that may influence suicide as it has been on the rise in Kenya.

-Road traffic accidents have a significant impact of the mental health of several Kenyans.

Recommendations.

-There should be more education regarding suicide prevention for NGOs.

-Corporate firms should look into providing observed health insurance and mental health days off in addition to more sick days for the affected.

-The government can implement policies and programs that provide more efficient facilities for the handling of observed health issues.

-Insurance companies can restructure their products around the knowledge that mental health issues in Kenya have a significant direct relationship to each other and also that the prevalence of alcohol and substance use critically impacts the road traffic death rate in Kenya.

-The government should critically look at the increase in the prevalence of alcohol...

BackgroundTo report the burden of cancers attributable to high fasting plasma glucose (HFPG) by sex, age, location, cancer type and Socio-demographic Index (SDI) over the period 1990 to 2019 for 204 countries and territories.MethodsUsing the Comparative Risk Assessment approach of Global Burden of Disease (GBD) study 2019, the burden of cancers attributable to HFPG was reported in 1990 and 2019.ResultsGlobally, in 2019 there were an estimated 419.3 thousand cancer deaths (95% UI: 115.7 to 848.5) and 8.6 million cancer DALYs (2.4 to 17.6) attributable to HFPG. By sex, 4.6 (1.1 to 9.9) and 4.0 (1.1 to 8.4) million global cancer DALYs were attributable to HFPG in men and women, respectively. The global age-standardized death and DALY rates of cancers attributable to HFPG (per 100,000) have increased by 27.8% (20.5 to 38.7%) and 24.5% (16.4 to 35.6%), respectively, since 1990. High-income North America (9.5 [2.7 to 18.8]) and Eastern Sub-Saharan Africa (2.0 [0.5 to 4.2]) had the highest and lowest regional age-standardized death rates, respectively, for cancers attributable to HFPG. In 2019, the global number of attributable cancer DALYs were highest in 65-69 age group. Moreover, there was an overall positive association between SDI and the regional age-standardized DALY rate for HFPG-attributable cancers.ConclusionsHFPG was associated with more burden in 2019. Preventive programs for diabetes and screening of individuals with diabetes for cancers, especially in older males living in developed countries, are required to arrest the large increases in HFPG-attributable cancers.

BackgroundThe purpose of this study is to assess the burden of thyroid cancer over the course of 30 years in 204 countries and territories.MethodsData from the Global Burden of Disease (GBD) 2019 database was analyzed to extract information on prevalence, deaths, DALYs(disability-adjusted life-years), YLL(years of life los), YLD(years lived with disability), and their corresponding age-standardized rates at global, regional, and national levels. The primary focus of the study was to examine trends in thyroid cancer from 1990 to 2019, specifically looking at the Estimated Annual Percentage Change (EAPC) for ASPR, ASDR, and ASDR. Additionally, the study investigated the relationship between cancer burden and the Socio-Demographic Index (SDI).ResultsGlobally, there will be approximately 18.3 million thyroid cancer (TC) cases in 2019; China and the USA are projected to be the most significant with 310,327 and 220,711 cases (16.17 and 14.82 cases per 100,000 people, respectively).Over the period from 1990 to 2019, age-standardized prevalence rates exhibited a global rise, whereas deaths and DALYs saw a decrease(EAPC:1.63, –0.15- –0.14, respectively). Significantly, the age-standardized prevalence rate increased in 21 GBD regions, affecting 195 out of 204 countries or territories. Over the studied period, thyroid cancer cases, deaths, and DALYs were consistently higher among females than males. Furthermore, a higher Socio-demographic Index was associated with increased age-standardized prevalence rates.

Similar Datasets

• Hepatitis C Dataset: LINK
• Body Fat Prediction Dataset: LINK
• Cirrhosis Prediction Dataset: LINK
• Stroke Prediction Dataset: LINK
• Stellar Classification Dataset - SDSS17: LINK
• Wind Speed Prediction Dataset: LINK
• Spanish Wine Quality Dataset: LINK
• Electric Power Consumption: LINK

Context

Since the start of the COVID-19 pandemic there have been over 290 million confirmed infections and 5 million deaths reported worldwide. Because of the unprecedented burden on healthcare resources, many healthcare activities such as chronic disease management, cancer screening and cancer treatments have been cancelled or delayed. Consequently, referrals of suspected new cancers have reduced, with increases in cancer-related deaths predicted.

The full impact of the COVID-19 pandemic on patients with primary liver cancer (PLC) has yet to be determined, although European data reported a disruption to hepatocellular carcinoma (HCC) services, a reduction in incident cases and an impact on management during the first wave of the pandemic (February 2020 to May 2020).

The data was prospectively collected on all patients referred to the Newcastle-upon-Tyne NHS Foundation Trust (NUTH) hepatopancreatobiliary multidisciplinary team (HPB MDT) in the first 12 months of the pandemic (March 2020-February 2021), comparing to a retrospective observational cohort of consecutive patients presenting in the 12 months immediately preceding it (March 2019-February 2020). All new cases with a diagnosis of hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma (ICC) confirmed radiologically or histologically, following international guidelines, were included.

The objective is to assess the impact of the COVID-19 pandemic on patients with newly diagnosed liver cancer.

Attribute Information

1. Cancer: Cancer flag [Y/N]
2. Year: Categorical [Prepandemic (March 2019–February 2020)/Postpandemic(March 2020–February 2021)]
3. Month: Month of the year 1-12
4. Bleed: Spontaneous tumour haemorrhage [Y/N]
5. Mode Presentation: Surveillance, Incidental, or Symptomatic
6. Age: Age of the patitent
7. Gender: Male or Female [M/F]
8. Etiology: manner of causation of a disease or condition. Either "No established CLD" (chronic liver disease), "ARLD" (alcohol-related liver disease), "NAFLD" (non-alcoholic fatty liver disease), "HCV" (hepatitis C virus), "HH" (hereditary haemochromatosis), "PBC/AIH" (primary biliary cholangitis/autoimmune hepatitis), "HBV" (hepatitis B virus), or "Other".
9. Cirrhosis: Underlying liver disease [Y/N]
10. Size: Tumour diameter in mm
11. HCC TNM Stage: Hepatocellular carcinoma Tumour node metastasis Stage ("I", "II", "IIIA+IIIB", "IV")
12. HCC BCLC Stage: Hepatocellular carcinoma Barcelona Clinic for Liver Cancer Stage ("0", "A", "B", "C", "D")
13. ICC TNM Stage: Intrahepatic cholangiocarcinoma Tumour node metastasis Stage ("I", "II", "III", "IV")
14. Treatment grps: First-line treatment received ["OLTx" (orthotopic liver transplantation), "Resection", "Ablation", "TACE"" (transarterial chemoembolisation), "SIRT" (selective internal radiation therapy), "Medical", "Supportive care"]
15. Survival from MDM: Survival from Multidisciplinary meeting
16. Alive Dead: "Alive", "Dead"
17. Type of incidental finding: ("Primary care-routine", "Secondary care-routine", "Primary care-acute", "Secondary care-acute")
18. Surveillance programme: Patient in a formal surveillance programme ("Y", "N")
19. Surveillance effectiveness: Surveillance adherence over previous year ("Consistent", "Inconsistent", "Missed")
20. Mode of surveillance detection: Mode of incident surveillance test ["US" (ultrasound), "AFP alone" (alpha-fetoprotein alone), "CT/MRI"]
21. Time diagnosis 1st Tx:
22. Date incident surveillance scan: ("Y", "N")
23. PS: Performance status [0, 1, 2, 3, 4]
24. Time MDM 1st treatment: Time to Multidisciplinary meeting 1st treatment
25. Time decision to treat 1st treatment: Time decision to treat 1st treatment
26. Prev known cirrhosis: ["Y", "N"]
27. Months from last surveillance: Months from last surveillance

Citation

fedesoriano. (September 2022). COVID-19 effect on Liver Cancer Prediction Dataset. Retrieved [Date Retrieved] from https://www.kaggle.com/datasets/fedesoriano/covid19-effect-on-liver-cancer-prediction-dataset.

Acknowledgeme...

Time series data for the statistic Mortality from CVD, cancer, diabetes or CRD between exact ages 30 and 70 (%) and country Canada. Indicator Definition:Mortality from CVD, cancer, diabetes or CRD is the percent of 30-year-old-people who would die before their 70th birthday from any of cardiovascular disease, cancer, diabetes, or chronic respiratory disease, assuming that s/he would experience current mortality rates at every age and s/he would not die from any other cause of death (e.g., injuries or HIV/AIDS).The indicator "Mortality from CVD, cancer, diabetes or CRD between exact ages 30 and 70 (%)" stands at 9.70 as of 12/31/2021. Regarding the One-Year-Change of the series, the current value constitutes a decrease of -3.00 percent compared to the value the year prior.The 1 year change in percent is -3.00.The 3 year change in percent is -1.02.The 5 year change in percent is -6.73.The 10 year change in percent is -11.01.The Serie's long term average value is 11.51. It's latest available value, on 12/31/2021, is 15.72 percent lower, compared to it's long term average value.The Serie's change in percent from it's minimum value, on 12/31/2019, to it's latest available value, on 12/31/2021, is +1.04%.The Serie's change in percent from it's maximum value, on 12/31/2000, to it's latest available value, on 12/31/2021, is -32.64%.

ObjectivesTo quantify the burden and variation trends of cancers in children under 5 years at the global, regional, and national levels from 1990 to 2019.MethodsEpidemiological data for children under 5 years who were diagnosed with any one childhood cancer were obtained from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) from 1990 to 2019. The outcomes were the absolute numbers and rates of incidence, prevalence, mortality, and disability-adjusted life-years (DALYs) for different types of cancer.ResultsIn 2019, 8,774,979.1 incident cases (95% uncertainty interval [UI]: 6,243,599.2 to11,737,568.5) and 8,956,583.8 (6,446,323.9 to 12,364,520.8) prevalent cases of cancer in children under 5 years were identified worldwide; these cancers resulted in 44,451.6 (36,198.7 to 53,905.9) deaths and 3,918,014.8 (3,196,454.9 to 4,751,304.2) DALYs. From 1990 to 2019, although the numbers of incident and prevalent cases only decreased by −4.6% (−7.0 to −2.2) and −8.3% (−12.6 to −3.4), respectively, the numbers of deaths and DALYs clearly declined by −47.8% (−60.7 to −26.4) and −47.7% (−60.7 to −26.2), respectively. In 2019, the middle sociodemographic index (SDI) regions had the highest incidence and prevalence, whereas the low SDI regions had the most mortality and DALYs. Although all of the SDI regions displayed a steady drop in deaths and DALYs between 1990 and 2019, the low-middle and low SDI regions showed increasing trends of incidence and prevalence. Leukemia remained the most common cancer globally in 2019. From 1990 to 2019, the burdens of leukemia, liver cancer, and Hodgkin's lymphoma declined, whereas the incidence and prevalence of other cancers grew, particularly testicular cancer.ConclusionsThe global childhood cancer burden in young children has been steadily decreasing over the past three decades. However, the burdens and other characteristics have varied across different regions and types of cancers. This highlights the need to reorient current treatment strategies and establish effective prevention methods to reduce the global burden of childhood cancer.

Time series data for the statistic Mortality from CVD, cancer, diabetes or CRD between exact ages 30 and 70 (%) and country Kiribati. Indicator Definition:Mortality from CVD, cancer, diabetes or CRD is the percent of 30-year-old-people who would die before their 70th birthday from any of cardiovascular disease, cancer, diabetes, or chronic respiratory disease, assuming that s/he would experience current mortality rates at every age and s/he would not die from any other cause of death (e.g., injuries or HIV/AIDS).The indicator "Mortality from CVD, cancer, diabetes or CRD between exact ages 30 and 70 (%)" stands at 44.10 as of 12/31/2021, the highest value at least since 12/31/2001, the period currently displayed. Regarding the One-Year-Change of the series, the current value constitutes an increase of 3.76 percent compared to the value the year prior.The 1 year change in percent is 3.76.The 3 year change in percent is 8.35.The 5 year change in percent is 6.01.The 10 year change in percent is 3.04.The Serie's long term average value is 42.42. It's latest available value, on 12/31/2021, is 3.95 percent higher, compared to it's long term average value.The Serie's change in percent from it's minimum value, on 12/31/2019, to it's latest available value, on 12/31/2021, is +8.62%.The Serie's change in percent from it's maximum value, on 12/31/2021, to it's latest available value, on 12/31/2021, is 0.0%.

BackgroundThis study aimed to comprehensively assess the global, regional, and national burden of esophageal cancer (EC) attributable to inadequate vegetable and fruit intake from 1990 to 2019 and explore the potential impact of existing dietary intervention programs on EC prevention.MethodsUsing the Global Burden of Disease Study 2019 (GBD 2019) database, we conducted descriptive analyses stratified by age, sex, Socio-demographic Index (SDI), and regional levels. Temporal trends were assessed using linear regression models, and cluster analysis was employed to explore burden patterns across different GBD regions. Decomposition analysis quantified the contributions of aging, population dynamics, and epidemiological changes to deaths and disability-adjusted life years (DALYs). Frontier analysis was used to evaluate the relationship between dietary risk-related disease burden and sociodemographic progress.ResultsIn 2019, inadequate vegetable and fruit intake contributed to 65,919 global EC deaths, accounting for 0.12% of all deaths, with an age-standardized death rate of 0.81 per 100,000 population. The associated DALYs totaled 16,065,68, representing 0.06% of total global DALYs, with an age-standardized DALY rate of 19.24. The disease burden attributable to insufficient fruit intake (51,210 deaths, 12,497,75 DALYs) was significantly higher than that from inadequate vegetable intake (17,176 deaths, 4,203,09 DALYs). The burden was greater in males than females, peaking in middle-aged groups. Substantial regional differences were observed, with low-SDI regions bearing the highest burden. From 1990 to 2019, while the absolute numbers of deaths and DALYs followed a complex trajectory of initial increase followed by decline, age-standardized rates consistently decreased, reflecting the positive impact of epidemiological improvements. Existing dietary intervention programs, such as subsidies for fruit and vegetable production and health education initiatives, have contributed to a reduction in dietary risk-related disease burden but exhibited varying effectiveness across SDI regions.ConclusionTargeted dietary interventions, such as promoting fruit and vegetable consumption, are critical for the prevention and control of the EC disease burden. Future efforts should focus on optimizing the implementation of current programs, enhancing nutritional supplementation in resource-limited regions, and expanding health education initiatives to achieve broader health benefits.

BackgroundTo estimate the burden of cancers attributable to high fasting plasma glucose (HFPG) by sex, age, location, cancer type and Socio-demographic Index (SDI) over the period 1990 to 2019 for 204 countries and territories.MethodsUsing the Comparative Risk Assessment approach of Global Burden of Disease (GBD) study 2019, the burden of cancers attributable to HFPG was estimated in 1990 and 2019.ResultsGlobally, in 2019 there were an estimated 419.3 thousand cancer deaths (95% UI: 115.7 to 848.5) and 8.6 million cancer DALYs (2.4 to 17.6) attributable to HFPG. By sex, 4.6 (1.1 to 9.9) and 4.0 (1.1 to 8.4) million global cancer DALYs were attributable to HFPG in men and women, respectively. The global age-standardized death and DALY rates of cancers attributable to HFPG (per 100,000) have increased by 27.8% (20.5 to 38.7%) and 24.5% (16.4 to 35.6%), respectively, since 1990. High-income North America (9.5 [2.7 to 18.8]) and Eastern Sub-Saharan Africa (2.0 [0.5 to 4.2]) had the highest and lowest regional age-standardized death rates, respectively, for cancers attributable to HFPG. In 2019, the global number of attributable cancer DALYs were highest in 65-69 age group. Moreover, there was an overall positive association between SDI and the regional age-standardized DALY rate for HFPG-attributable cancers.ConclusionsHFPG was associated with more burden in 2019. Preventive programs for diabetes and screening of individuals with diabetes for cancers, especially in older males living in developed countries, are required to arrest the large increases in HFPG-attributable cancers.

Background: Ambient particulate matter is a public health concern in East Asia as it contributes to a growing number of all-cause and cancer deaths. This study aimed to estimate lung cancer death attributable to ambient particulate matter (PM) < 2.5 μm (PM2.5) in East Asia countries.Methods: The attributable death rates of lung cancer were estimated based on the calculation of population attributable fraction. We performed joinpoint regression analysis and age-period-cohort (APC) model to estimate temporal trends of the attributable death to PM2.5.Results: In 2019, PM2.5 was estimated to have caused 42.2% (nearly 0.13 million) of lung cancer deaths in East Asia men. During 1990–2019, the increase in age-standardized death rates of lung cancer attributable to PM2.5 was highest in China, which increased by 3.50% in males and 3.71% in females. The death rate caused by PM2.5 also significantly increased in the Democratic People's Republic of Korea (2.16% in males; 3.06% in females). Joinpoint analysis showed that the rates generally increased in younger and older people in both the Democratic People's Republic of Korea and Mongolia, while it only increased in elderly people in other countries'. Age effect from APC analysis demonstrated the risk of lung cancer death attributable to PM2.5 generally increased from young to old age. Period effect indicated that from 1994–1998 to 2019–2023 period risk continuously increased by 1.77, 1.68, and 1.72 times in China, the Democratic People's Republic of Korea, and Japan, respectively. The period risk decreased from 1999 to 2009 and subsequently increased from 2009 to 2019 in both the Republic of Korea and Mongolia.Conclusions: The death rate of lung cancer attributable to PM2.5 is increasing in the Democratic People's Republic of Korea, Mongolia, and China. In East Asia, China is facing the highest attributable death rate in recent decades. The period effect suggested a remarkably increased risk of lung cancer death caused by PM2.5 in China, the Democratic People's Republic of Korea, and Japan during the long-term period. It is recommended that the governments of these countries should continuously concentrate on particulate matter pollution governance and improvement.

Определение: Уровень смертности от сердечно-сосудистых заболеваний, рака, диабета или хронических респираторных заболеваний. Вероятность смерти в возрасте от 30 до 70 лет от сердечно-сосудистых заболеваний, рака, диабета или хронических респираторных заболеваний, определяемая как процент 30-летних людей, которые умрут до своего 70-летия от сердечно-сосудистых заболеваний, рака, диабета или хронических респираторных заболеваний, при условии, что они/у него были бы текущие показатели смертности в любом возрасте, и он/она не умер бы ни от какой другой причины смерти (например, от травм или ВИЧ/СПИДа). Этот показатель рассчитывается с использованием методов таблицы продолжительности жизни (более подробную информацию смотрите в разделе 3.3). [Переведено с en: английского языка] Тематическая область: Цели в области устойчивого развития [Переведено с en: английского языка] Область применения: ПОКАЗАТЕЛЬ 3.4.1 Уровень смертности от сердечно-сосудистых заболеваний, рака, диабета или хронических респираторных заболеваний [Переведено с en: английского языка] Единица измерения: Номер [Переведено с en: английского языка] Источник данных: Оценки глобального здравоохранения на 2019 год: Смертность в разбивке по причинам, возрасту, полу, странам и регионам, 2000-2019 гг. Женева, Всемирная организация здравоохранения, 2020 г. [Переведено с es: испанского языка] Последнее обновление: Jan 8 2024 1:20AM Организация-источник: Глобальная база данных Организации Объединенных Наций по ЦУР [Переведено с en: английского языка] Definition: Mortality rate attributed to cardiovascular disease, cancer, diabetes or chronic respiratory disease. Probability of dying between the ages of 30 and 70 years from cardiovascular diseases, cancer, diabetes or chronic respiratory diseases, defined as the per cent of 30-year-old-people who would die before their 70th birthday from cardiovascular disease, cancer, diabetes, or chronic respiratory disease, assuming that s/he would experience current mortality rates at every age and s/he would not die from any other cause of death (e.g., injuries or HIV/AIDS). This indicator is calculated using life table methods (see further details in section 3.3). Thematic Area: Sustainable Development Goals Application Area: INDICATOR 3.4.1 Mortality rate attributed to cardiovascular disease, cancer, diabetes or chronic respiratory disease Unit of Measurement: Number Data Source: Global Health Estimates 2019: Deaths by Cause, Age, Sex, by Country and by Region, 2000-2019. Geneva, World Health Organization, 2020 Last Update: Jan 8 2024 1:20AM Source Organization: United Nations Global SDG Database

Our study is the first to illustrate the age and geographic distribution differences in the epidemiology of prostate cancer from 1990 to 2019 in China. Prostate cancer (PC) is a malignant tumor derived from prostate epithelial cells and is one of the most commonly diagnosed cancers in men. In recent years, the global incidence and the annual deaths number of PC showed a continuous increase, which has caused a huge disease burden on human health. In terms of the global average, the incidence and mortality of PC in China are relatively low. However, the age-standardized incidence rate of PC was 17.3/100,000 in 2019 in China, with a 95.2% rise compared to 1990, while the global growth rate of incidence rate over the same period is 13.2%. This showed that the development trend of PC in China is not optimistic. There are few precise studies on the epidemiology of PC in China. After the general analysis strategy used in the Global Burden of Diseases, Injuries and Risk Factors Study (GBD) 2019, we elaborated on the incidence, mortality, and disability-adjusted life-years (DALYs) and the corresponding age-standardized rate of the Chinese PC population from 1990 to 2019 according to different ages and provinces. We used joinpoint regression analysis to estimate the incidence and mortality trends. Our analysis shows that elderly people over 80 are still the main focus of incidence and death. The epidemiology and disease burden of PC of different provinces in China show obvious regional differences, and some certain provinces such as HongKong, Macao, and Zhejiang should be paid more attention. More targeted and effective strategies should be developed to reduce the burden of PC in China.

The Cohort of Swedish Men is a large population-based cohort of over 45,000 men in the counties of Västmanland and Örebro. All men born 1918-1952 who were residing in Västmanland and Örebro County in 1997 received an invitation to participate in this research study and a questionnaire to answer and return. Approximately 48,000 men responded. Follow-ups were done during 2008/2009 and 2019. The study examine associations of environmental/modifiable risk factors with several cancer sites (e.g., prostate, colorectal and renal cell cancer), myocardial infarction, stroke, cataracts, as well as death causes. The study has a longitudinal design, and to complement the update on exposure data record linkages to the nationwide Cancer Register, the In-Patient Register, and the Cause of Death Register and Population Register are also done.

The questionnaires used in the Cohort of Swedish men are the same as the ones that have been used in the Swedish Mammography Cohort (SMC). For updated information on questionnaires and variable lists please visit https://www.simpler4health.se/researchers/.

Purpose:

The general aim of the Cohort of Swedish Men (COSM) is to assess relationships between a number of modifiable factors (diet, vitamin supplement use, physical activity, smoking, alcohol, body weight, other anthropometric measures etc.) and the occurrence of several major chronic diseases.

For more detailed information please visit the SIMPLER website, https://www.simpler4health.se/researchers/cohorts/.

For restrictions in data use see https://www.simpler4health.se/researchers/rules-and-guidelines/ and https://www.simpler4health.se/researchers/publication-policy/.

Using the same version of the questionnaire as in 2008 the Health questionnaire was sent in January 2019 to all living participants in the cohort. The questionnaire can be found at https://www.simpler4health.se/researchers/questionnaires/.